Table 3. Correlational analyses between PD1⁺ICOS⁺ Tfh-like subsets and antibody titers at D30 and M7.

	Antibodies at D30		Antibodies at M7
Gardasil	Anti-HPV16 (r/p) a	Anti-HPV18 (r/p)	Anti-HPV16 (r/p)	Anti-HPV18 (r/p)
PD1+ ICOS+ Tfh1 at D7	NS b	(0.675 / 0.0372)	NS	NS
PD1+ ICOS+ Tfh2 at D7	NS	NS	NS	NS
PD1+ ICOS+ Tfh17 c at D7	NS	NS	NS	NS
Cervarix	Anti-HPV16 (r/p)	Anti-HPV18 (r/p)	Anti-HPV16 (r/p)	Anti-HPV18 (r/p)
PD1+ ICOS+ Tfh1 at D7	NS	NS	NS	NS
PD1+ ICOS+ Tfh2 at D7	NS	NS	NS	NS
PD1+ ICOS+ Tfh17 at D7	NS	NS	NS	NS

Fold changes in different Tfh-like subsets (indicated as Tfh1, Tfh2, and Tfh17) at D7 over the pre-vaccinated time point were compared to the fold changes in the antibody titers at the indicated time points (over the pre-vaccinated time points).

^a r indicates correlation coefficient from Spearman correlation rank analyses; p indicates p value from the Spearman correlational rank analyses.

^b NS, not significant.

^c The frequencies of Tfh17 subsets in some subjects were 0% at the base line; therefore, we could not analyze some of the subjects. For the Tfh1- and 2 subsets, 10 subjects for Gardasil were compared, and it was 8 for Cervarix for D30. For M7, the numbers ranged 5–8 in both groups.